RT Journal Article
SR Electronic
T1 SARS-CoV-2 in wastewater treatment plants
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.04.20122218
DO 10.1101/2020.06.04.20122218
A1 Collivignarelli, Maria Cristina
A1 Collivignarelli, Carlo
A1 Carnevale Miino, Marco
A1 Abbà, Alessandro
A1 Pedrazzani, Roberta
A1 Bertanza, Giorgio
YR 2020
UL http://medrxiv.org/content/early/2020/06/08/2020.06.04.20122218.abstract
AB As for the SARS coronavirus in the 2003 epidemic, the presence of SARS-CoV-2 has been demonstrated in faeces and, in some cases, urine of infected people, as well as in wastewater. This paper proposes a critical review of the state of the art regarding studies on the presence of SARS-CoV-2 in wastewater and sewage sludge, the factors affecting its inactivation and the main proposed treatments, with the aim to provide useful information at operative level in order to better and safer manage wastewater and sewage sludge. Given the lack of literature on SARS-CoV-2, studies involving other HCoVs such as SARS-CoV and HCoV-229E have been also considered. In wastewater, the resistance of SARS-CoV has proven to be very limited, especially at temperatures above 20 °C, and the virus has been easily removed with the use of chlorine (> 0.5 mg L−1 for 30 min). For sewage sludge, based on in vitro experiments, it is suggested to increase the retention times before a possible reuse in agriculture only for precautionary purposes, since SARS-CoV-2 is unlikely to occur in the sludge. SARS-CoV-2 in wastewater might track the epidemic trends: although being extremely promising, an effective and wide application of this approach requires a deeper knowledge of the amounts of viruses excreted through the faeces and the actual detectability of viral RNA in sewage.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo fundings received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Nothing to declare.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNothing to declare.